Sionna Therapeutics, Inc. Common Stock (SION) - Total Liabilities
Based on the latest financial reports, Sionna Therapeutics, Inc. Common Stock (SION) has total liabilities worth $19.12 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Sionna Therapeutics, Inc. Common Stock long-term investment intensity to see how much of total assets are deployed in long-term investments.
Sionna Therapeutics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Sionna Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Sionna Therapeutics, Inc. Common Stock (SION) total assets.
Sionna Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Sionna Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MM Forgings Limited
NSE:MMFL
|
India | Rs15.56 Billion |
|
BLD Plantation Bhd
KLSE:5069
|
Malaysia | RM477.97 Million |
|
Everyday Network
SHE:300295
|
China | CN¥89.40 Million |
|
Yuen Foong Yu Consumer Prod
TW:6790
|
Taiwan | NT$4.66 Billion |
|
Galectin Therapeutics Inc
NASDAQ:GALT
|
USA | $146.00 Million |
|
Ve Wong Corp
TW:1203
|
Taiwan | NT$3.14 Billion |
|
Gérard Perrier Industrie S.A.
PA:PERR
|
France | €184.96 Million |
|
Lands’ End Inc
NASDAQ:LE
|
USA | $404.58 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Sionna Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Sionna Therapeutics, Inc. Common Stock to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sionna Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sionna Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.12 Million | -94.53% |
| 2024-12-31 | $349.46 Million | +109.48% |
| 2023-12-31 | $166.83 Million | +6.06% |
| 2022-12-31 | $157.29 Million | -- |
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more